Identification of novel factors to expand hematopoietic stem cells in vitro

Projektinformationen

NOVEXPAND

ID Finanzhilfevereinbarung: 253463

Abgeschlossenes Projekt

Startdatum 1 Januar 2011

Enddatum 31 Dezember 2012

Finanziert unter

• Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Gesamtkosten € 180 669,40

EU-Beitrag € 180 669,40

Koordiniert durch

MAX IV Laboratory, Lund University
Sweden

Ziel

Blood and marrow transplantation (BMT) has been used successfully to treat malignant blood disorders and genetic diseases. Although BMT has been effective, problems remain, for example lack of suitable donors and engraftment failure. Cord blood (CB) contains hematopoietic stem cells (HSC) that can be used to transplant children. However, there are too few HSC in most CB samples to reliably engraft adult patients following BMT. Development of HSC expansion prior to transplantation would allow successful engraftment in patients that cannot be transplanted today due to a lack of a suitable donor. While some classical cytokines can maintain the number of HSC in culture, expansion of HSC in vitro will require discovery of novel factors that can increase more symmetrical divisions of HSC. In this project we will identify new factors that can expand HSCs by increasing the proliferation of immature HSC, using recent findings from embryonic stem (ES) cells and induced pluripotent stem (iPS) cells. ES/iPS cells are cell lines that have strong proliferation ability and are pluripotent in the presence of defined factors. Several genes expressed in ES/iPS cells have been identified as stem cell regulators, but a comprehensive analysis of all possible genes is essential to find additional factors that may be important for expansion of HSC. The screening will be done by using microarray analysis, subtraction assay, and over expression using cDNA libraries. Genes that are differentially expressed in immature ES cells and differentiated cells will be inserted into lentiviral vectors and transduced to HSC. The transduced HSCs will be analyzed with respect to inceased stem cell function using a transplantation assay in vivo. Findings from the project are expected to discover several novel regulatory molecules that will allow HSC expansion prior to transplantation. Successful HSC expansion will make most CB donor samples useful for adults requiring HSC transplantation therapy.

Wissenschaftliches Gebiet

• medical and health sciences › medical biotechnology › cells technologies › stem cells
• medical and health sciences › clinical medicine › hematology
• medical and health sciences › clinical medicine › transplantation

Programm/Programme

• FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Thema/Themen

• FP7-PEOPLE-2009-IIF - Marie Curie Action: "International Incoming Fellowships"

Aufforderung zur Vorschlagseinreichung

FP7-PEOPLE-2009-IIF
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

MC-IIF - International Incoming Fellowships (IIF)

Koordinator

MAX IV Laboratory, Lund University

Kontakt Verwaltung

Jens Forsberg (Dr.)

• EU-Beitrag: € 180 669,40
• Adresse: Paradisgatan 5c ; 22100 LUND ; Schweden
• Region: Södra Sverige › Sydsverige › Skåne län
• Aktivitätstyp: Higher or Secondary Education Establishments
• Gesamtkosten: Keine Daten